Anupam Rasayan Q2 FY27 Revenue Up 11% to ₹821 Cr, PAT Grows 14%
Anupam Rasayan India Limited reported Q2 FY27 revenue of ₹821 crore, up 11% YoY. PAT grew 14% to ₹65 crore. H1 FY27 revenue increased 21% to ₹1,489 crore. The company signed a six-year supply agreement and acquired a 50.07% stake in Bliss GVS Pharma.
The strong financial performance, coupled with a long-term supply agreement and a controlling stake acquisition in a pharmaceutical company, indicates significant positive developments for the company's future growth and market position.
The company reported strong year-on-year growth in revenue and profit for both the quarter and half-year, along with strategic achievements like a long-term supply agreement and a significant acquisition.
Anupam Rasayan India Limited announced its unaudited financial results for the quarter and half-year ended September 30, 2026. The company reported its highest-ever quarterly consolidated revenue during Q2 FY27.
For the quarter ended September 30, 2026 (Q2FY27), Anupam Rasayan recorded a total revenue of ₹821 crore, an increase of 11% compared to ₹739 crore in Q2FY26. EBITDA for the quarter rose by 41% to ₹202 crore from ₹144 crore in the previous year, with the EBITDA margin improving to 25% from 19%. Profit After Tax (PAT) for Q2FY27 stood at ₹65 crore, a 14% increase from ₹57 crore in Q2FY26.
For the half-year ended September 30, 2026 (H1FY27), total revenue grew by 21% year-on-year to ₹1,489 crore from ₹1,230 crore in H1FY26. EBITDA for the half-year increased by 38% to ₹377 crore from ₹273 crore, resulting in an EBITDA margin of 25%. PAT for H1FY27 was ₹116 crore, up 10% from ₹106 crore in H1FY26.
Mr. Anand Desai, Managing Director, highlighted the strategic priorities, expansion into new end markets, and strengthening of the business portfolio. He noted the resilience of the diversified business and progress across key segments. During the quarter, the company signed a six-year supply agreement with a US-based specialty metal manufacturer and completed the acquisition of a 50.07% stake in Bliss GVS Pharma, aiming to build a diversified pharmaceutical platform.
What to do with a filing like this
Anupam Rasayan India Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Anupam Rasayan India Limited. Read the original for the full detail.